A recent real-world study confirms that brexucabtagene autoleucel (brexu-cel) is safe and effective for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), matching results from the pivotal ZUMA-3 trial. The study looked at 292 patients treated between 2021 and 2024 and found similar or slightly lower rates of serious side effects compared to […]
Pathologists are taking on a larger role in managing non-small cell lung cancer, moving beyond diagnosis to help guide treatment decisions. They now act as “first responders,” automatically starting molecular testing as soon as cancer is detected, which helps patients begin therapy more quickly. They also assess whether small biopsy samples have enough tumor material
Pathologists Take Leading Role in Guiding non-small cell lung cancer Treatment Read More »
The U.S. Food and Drug Administration has approved nivolumab (Opdivo) in combination with chemotherapy (AVD) to treat adults and children aged 12 and older with advanced classical Hodgkin lymphoma who have not received prior treatment. The drug was also fully approved for adults whose disease has returned or not responded after stem cell transplant or
Doctors are changing how they treat brain metastases in lung cancer, with more patients now starting on targeted drug therapy instead of immediate radiation or surgery. For patients without symptoms who have specific genetic mutations such as EGFR, ALK, ROS1, or RET, doctors are increasingly using modern tyrosine kinase inhibitors (TKIs) first. These drugs can
Targeted Therapies Take Lead in Treating Lung Cancer Brain Metastases Read More »
Researchers from Mass General Brigham and Dana-Farber Cancer Institute have developed a new treatment for glioblastoma, a highly aggressive brain cancer that often resists immunotherapy. The therapy uses a genetically engineered herpes simplex virus that selectively infects and kills tumor cells while sparing healthy brain tissue. As it replicates, the virus destroys cancer cells and
Engineered herpes simplex virus Shows Promise Against Deadly glioblastoma in Early Trial Read More »
Researchers have developed a more advanced version of an oncolytic vaccinia virus, designed to safely target and kill cancer cells while sparing healthy tissue. Although this type of “living drug” has shown promise, earlier versions faced key challenges, including safety concerns from uncontrolled viral spread, risk of infecting others through skin lesions, and difficulty tracking
Engineered Oncolytic Virus with Built-In Safety Switch Advances to Clinical Trials Read More »
A new study reports a promising cell therapy for osteosarcoma, a bone cancer that is especially difficult to treat once it spreads. While survival rates for localized disease are about 70%, they fall below 30% when the cancer metastasizes, most often to the lungs. Treatment options have remained largely unchanged for decades, relying on surgery
Engineered CAR-NK Cell Therapy Shows Promise Against Metastatic Osteosarcoma Read More »
A new study reports a promising cancer treatment strategy using a peptide called 1H13, designed to target survivin—a protein that helps cancer cells avoid death. Survivin is highly expressed in tumors but largely absent in normal adult tissues, making it an attractive therapeutic target. Previous attempts to block survivin have had limited success, but this
Multi-Target Survivin Peptide Shows Strong Tumor Reduction in Early Cancer Study Read More »
A Phase 2 trial tested the combination of Azacitidine and Pembrolizumab as a second-line treatment for advanced pancreatic ductal adenocarcinoma. The goal was to “prime” the tumor with Azacitidine to make it more visible to the immune system and improve response to immunotherapy. The study enrolled 36 patients, with 31 evaluable for efficacy. Results showed
ChemoSeed, a new implantable drug-delivery system, has received Orphan Drug Designation from the FDA for treating aggressive high-grade gliomas, including glioblastoma. Traditional chemotherapy often struggles to reach brain tumors due to the blood-brain barrier. ChemoSeed overcomes this by using tiny biodegradable implants placed directly into the tumor or surgical site. These “seeds” release Irinotecan over
FDA Grants Orphan Drug Status to ChemoSeed for Aggressive high-grade gliomas Read More »